[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,677
Citations 0
This Week in JAMA
June 20, 2012

This Week in JAMA

JAMA. 2012;307(23):2461. doi:10.1001/jama.2012.3048

To assess whether routinely used cardiovascular disease (CVD) risk prediction scores can be improved by replacing or supplementing traditional cholesterol measurements with emerging lipid-related markers, investigators from the Emerging Risk Factors Collaboration analyzed data from 165 544 individuals (37 prospective cohort studies) who did not have CVD at baseline. Among the study findings were that the addition of information on the combination of apolipoprotein B and A-I, lipoprotein A, or lipoprotein-associated phospholipase A2 mass to risk scores containing total cholesterol and high-density lipoprotein cholesterol resulted in slight improvement in CVD risk prediction. In an editorial, Grundy discusses lipoprotein measures and CVD risk prediction.